Loading...

ELISA MAX™ Deluxe Set Human IFN-γ ELISA MAX™ Deluxe Set Human IFN-γ

Pricing & Availability
Regulatory Status
RUO
Other Names
IFN-g ELISA Kit
Ave. Rating
Submit a Review
Product Citations
publications
human ifn-g_121609
  • human ifn-g_121609
Cat # Size Price Quantity Check Availability Save
430104 5 plates NOK2517
Check Availability


Need larger quantities of this item?
Request Bulk Quote
430115 10 Plates NOK4835
Check Availability


Need larger quantities of this item?
Request Bulk Quote
430116 20 Plates NOK7739
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

ELISA Development Systems Engineered for Sensitive, Precise and Reliable Serum and Plasma Cytokine Quantitation

BioLegend's ELISA Max™ Sets provide all the time-savings, convenience and performance of a high-end, commercial ELISA kit for a fraction of the price!

BioLegend's ELISA Max™ Sets, in two appealing formats, address the need for sensitivity, accuracy, dependability, and versatility of an ELISA development system, while providing maximum cost effectiveness, value, and ease of use.

Both the ELISA Max™ Set Standard and ELISA Max™ Set Deluxe are specifically engineered for accurate recovery and measurement of analytes in complex fluids, such as serum and plasma (as well as activated cell cultures) without any interference by confounding serum factors, such as heterophilic antibody or rheumatoid factor.

Product Details
Technical Data Sheet (pdf)

Kit Details

Kit Contents
  • Human IFN-γ ELISA MAX™ Capture Antibody (200X)
  • Human IFN-γ ELISA MAX™ Detection Antibody (200X)
  • Human IFN-γ Standard
  • Avidin-HRP (1000X)
  • Substrate Solution D
  • Coating Buffer A (5X)
  • Assay Diluent A (5X)

Older lots of these products may contain Substrate Solutions A and B instead of Substrate Solution D mentioned on the TDS and the current manual. Please refer to the lot-specific CoA for the list of the reagents included in the lot and follow the ELISA procedure provided there.

Materials Not Included
  • Microwell plates: 96-well Nunc MaxiSorp™ is recommended.
  • A microplate reader capable of measuring absorbance at 450 nm
  • Adjustable pipettes to measure volumes ranging from 2 µL to 1 mL
  • Deionized (DI) water
  • PBS (Phosphate-Buffered Saline): 8.0 g NaCl, 1.16 g Na2HPO4, 0.2 g KH2PO4, 0.2 g KCl, add deionized water to 1 L; pH to 7.4, 0.2 µm filtered.
  • Wash Buffer (Phosphate-Buffered Saline (PBS) + 0.05% Tween-20, pH=7.4). BioLegend Cat. No. 421601 is recommended.
  • Wash bottle or automated microplate washer
  • Stop Solution (e.g. 2N H2SO4) Biolegend Cat. No. 423001 is recommended
  • Log-Log graph paper or software for data analysis
  • Tubes to prepare standard dilutions
  • Timer
  • Plate Sealer
  • Absorbent paper

Product Details

Verified Reactivity
Human
Application

ELISA
 
As a part of BioLegend's efforts to go green, each new lot of the ELISA MAX™ sets will include a summarized version of its manual. Click here for more information.
Application Notes

The assay kits will no longer include ELISA microwell plates. Recommended microwell plates can be purchased separately under Cat. No. 423501. Please contact your BioLegend sales representative for bulk pricing quotations.

Application References
  1. Ye Z, et al. 2008. Infect Immun. 75:2541. PubMed
  2. Zhang Y, et al. 2010. Infect Immun. 78:2329. PubMed
  3. Peng J, et al. 2005. J. Immunother. 28:599. PubMed
  4. Bendersky A, et al. 2012. J. Immunol. 188:4349. PubMed
  5. Boggio E, et al. 2012. Hum Immunol. 73:585. PubMed
  6. Ankrum JA, et al. 2014. Sci Rep. 4:4645. PubMed
  7. Wu Z, et al. 2015. J Virol. 89:2906. PubMed
Product Citations
  1. Klement JD, et al. 2018. J Clin Invest. 128:5549. PubMed
  2. Wu Z, et al. 2015. J Virol. 89:2906. PubMed
  3. Cordoba S, et al. 2021. Nat Med. 27:1797. PubMed
  4. Heitzeneder S, et al. 2022. Cancer Cell. 40:53. PubMed
  5. Shemesh A, et al. 2022. J Exp Med. 219: . PubMed
  6. Bigenwald C, et al. 2023. Oncoimmunology. 12:2163785. PubMed
  7. Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed
  8. Labanieh L, et al. 2022. Cell. 185:1745. PubMed
  9. McKenzie C, et al. 2023. Mol Ther Nucleic Acids. 32:603. PubMed
  10. Leland P, et al. 2023. J Transl Med. 21:367. PubMed
  11. Loh HP, et al. 2023. MAbs. 2231129:15. PubMed
  12. Scurr MJ, et al. 2022. Nat Commun. 13:5422. PubMed
  13. Bröker K, et al. 2019. J Transl Med. 17:6. PubMed
  14. Meryk A et al. 2019. Cell reports. 26(10):2681-2691 . PubMed
  15. Kilcollins A, et al. 2016. J Immunol. 197: 419 - 428. PubMed
  16. Pires D, et al. 2021. Front Immunol. 12:742822. PubMed
  17. Singhal J, et al. 2022. Front Cell Infect Microbiol. 12:878136. PubMed
  18. Wang H, et al. 2021. J Immunother Cancer. 9:. PubMed
  19. Singh N, et al. 2018. PLoS One. 13:e0199817. PubMed
  20. Boggio E, et al. 2012. Hum Immunol. 73:585. PubMed
  21. Booty MG, et al. 2022. J Immunol. 208:929. PubMed
  22. Bendersky A, et al. 2012. J Immunol. 188:4349. PubMed
  23. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  24. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  25. Ankrum J, et al. 2014. Sci Rep. 4:4645. PubMed
  26. You Y, et al. 2021. Mol Med Rep. 24:. PubMed
  27. Karampetsou M, et al. 2016. J Immunol. 196: 4915 - 4924. PubMed
  28. Aldeghaither DS, et al. 2019. Cancer Immunol Res. 7:230. PubMed
  29. Kofla G, et al. 2022. Oncoimmunology. 11:2068109. PubMed
  30. Godbersen C, et al. 2017. Mol Cancer Ther. 16:1335. PubMed
  31. Sp N, et al. 2021. Int J Mol Sci. 22:. PubMed
  32. Hirschberger S, et al. 2022. Front Med (Lausanne). 9:923502. PubMed
  33. Liu CA, et al. 2022. Cancers (Basel). 14:. PubMed
  34. Madison BB, et al. 2022. Mol Ther Nucleic Acids. 29:979. PubMed
  35. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  36. Fernandes RA, et al. 2020. Nature. 779:586. PubMed
  37. Bliska Y 2010. Infect Immun. 78:2359. PubMed
  38. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  39. Wu Z, et al. 2019. Microorganisms. 0.670833333. PubMed
  40. Trinklein ND, et al. 2019. MAbs. 11:639. PubMed
  41. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  42. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  43. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  44. Subramanian N, et al. 2017. J Gen Virol. 98(12). PubMed
  45. Zhang X, et al. 2019. Hematol Oncol. 37(3):270. PubMed
  46. Kang CH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  47. Iraqi M, et al. 2022. Int J Mol Sci. 23:. PubMed
  48. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  49. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  50. Dammermann W, et al. 2017. J Virol Methods. 10.1016/j.jviromet.2017.07.011. PubMed
  51. Wang E, et al. 2015. Cancer Immunol Res. 3: 815 - 826. PubMed
  52. Kunyanee C, et al. 2016. PLoS One. 11: 0160741. PubMed
  53. Lei W, et al. 2022. Blood Cancer J. 12:35. PubMed
  54. Lucchesi D, et al. 2020. Arthritis Rheumatol. 1559:72. PubMed
  55. Singh N, et al. 2017. Mol Immunol. 85:111. PubMed
  56. Klement JD, et al. 2018. J Clin Invest. 128:5549. PubMed
  57. Wu Z, et al. 2015. J Virol. 89:2906. PubMed
  58. Cordoba S, et al. 2021. Nat Med. 27:1797. PubMed
  59. Heitzeneder S, et al. 2022. Cancer Cell. 40:53. PubMed
  60. Shemesh A, et al. 2022. J Exp Med. 219: . PubMed
  61. Bigenwald C, et al. 2023. Oncoimmunology. 12:2163785. PubMed
  62. Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed
  63. Labanieh L, et al. 2022. Cell. 185:1745. PubMed
  64. McKenzie C, et al. 2023. Mol Ther Nucleic Acids. 32:603. PubMed
  65. Leland P, et al. 2023. J Transl Med. 21:367. PubMed
  66. Loh HP, et al. 2023. MAbs. 2231129:15. PubMed
  67. Scurr MJ, et al. 2022. Nat Commun. 13:5422. PubMed
  68. Bröker K, et al. 2019. J Transl Med. 17:6. PubMed
  69. Meryk A et al. 2019. Cell reports. 26(10):2681-2691 . PubMed
  70. Kilcollins A, et al. 2016. J Immunol. 197: 419 - 428. PubMed
  71. Pires D, et al. 2021. Front Immunol. 12:742822. PubMed
  72. Singhal J, et al. 2022. Front Cell Infect Microbiol. 12:878136. PubMed
  73. Wang H, et al. 2021. J Immunother Cancer. 9:. PubMed
  74. Singh N, et al. 2018. PLoS One. 13:e0199817. PubMed
  75. Boggio E, et al. 2012. Hum Immunol. 73:585. PubMed
  76. Booty MG, et al. 2022. J Immunol. 208:929. PubMed
  77. Bendersky A, et al. 2012. J Immunol. 188:4349. PubMed
  78. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  79. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  80. Ankrum J, et al. 2014. Sci Rep. 4:4645. PubMed
  81. You Y, et al. 2021. Mol Med Rep. 24:. PubMed
  82. Karampetsou M, et al. 2016. J Immunol. 196: 4915 - 4924. PubMed
  83. Aldeghaither DS, et al. 2019. Cancer Immunol Res. 7:230. PubMed
  84. Kofla G, et al. 2022. Oncoimmunology. 11:2068109. PubMed
  85. Godbersen C, et al. 2017. Mol Cancer Ther. 16:1335. PubMed
  86. Sp N, et al. 2021. Int J Mol Sci. 22:. PubMed
  87. Hirschberger S, et al. 2022. Front Med (Lausanne). 9:923502. PubMed
  88. Liu CA, et al. 2022. Cancers (Basel). 14:. PubMed
  89. Madison BB, et al. 2022. Mol Ther Nucleic Acids. 29:979. PubMed
  90. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  91. Fernandes RA, et al. 2020. Nature. 779:586. PubMed
  92. Bliska Y 2010. Infect Immun. 78:2359. PubMed
  93. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  94. Wu Z, et al. 2019. Microorganisms. 0.670833333. PubMed
  95. Trinklein ND, et al. 2019. MAbs. 11:639. PubMed
  96. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  97. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  98. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  99. Subramanian N, et al. 2017. J Gen Virol. 98(12). PubMed
  100. Zhang X, et al. 2019. Hematol Oncol. 37(3):270. PubMed
  101. Kang CH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  102. Iraqi M, et al. 2022. Int J Mol Sci. 23:. PubMed
  103. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  104. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  105. Dammermann W, et al. 2017. J Virol Methods. 10.1016/j.jviromet.2017.07.011. PubMed
  106. Wang E, et al. 2015. Cancer Immunol Res. 3: 815 - 826. PubMed
  107. Kunyanee C, et al. 2016. PLoS One. 11: 0160741. PubMed
  108. Lei W, et al. 2022. Blood Cancer J. 12:35. PubMed
  109. Lucchesi D, et al. 2020. Arthritis Rheumatol. 1559:72. PubMed
  110. Singh N, et al. 2017. Mol Immunol. 85:111. PubMed
Sensitivity
4 pg/mL
Standard Range
7.8-500 pg/mL

Antigen Details

Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Type
Tregs
Biology Area
Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Gene ID
3458 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

Do the ELISA MAX™ Deluxe Sets come with plates?

No, ELISA MAX™ Deluxe Sets do not come with plates. Coating Buffer and Assay Diluent (for blocking and dilutions) are included in these sets. Plates can be ordered separately (Cat No. 423501), and instructions for coating the plates are in the sets’ product manuals.

Go To Top Version: 6    Revision Date: 07.15.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Pricing & Availability
Regulatory Status
RUO
Other Names
IFN-g ELISA Kit
Ave. Rating
Submit a Review
Product Citations
publications
human ifn-g_121609
  • human ifn-g_121609
Cat # Size Price Quantity Check Availability Save
430104 5 plates NOK2517
Check Availability


Need larger quantities of this item?
Request Bulk Quote
430115 10 Plates NOK4835
Check Availability


Need larger quantities of this item?
Request Bulk Quote
430116 20 Plates NOK7739
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

ELISA Development Systems Engineered for Sensitive, Precise and Reliable Serum and Plasma Cytokine Quantitation

BioLegend's ELISA Max™ Sets provide all the time-savings, convenience and performance of a high-end, commercial ELISA kit for a fraction of the price!

BioLegend's ELISA Max™ Sets, in two appealing formats, address the need for sensitivity, accuracy, dependability, and versatility of an ELISA development system, while providing maximum cost effectiveness, value, and ease of use.

Both the ELISA Max™ Set Standard and ELISA Max™ Set Deluxe are specifically engineered for accurate recovery and measurement of analytes in complex fluids, such as serum and plasma (as well as activated cell cultures) without any interference by confounding serum factors, such as heterophilic antibody or rheumatoid factor.

Product Details
Technical Data Sheet (pdf)

Kit Details

Kit Contents
  • Human IFN-γ ELISA MAX™ Capture Antibody (200X)
  • Human IFN-γ ELISA MAX™ Detection Antibody (200X)
  • Human IFN-γ Standard
  • Avidin-HRP (1000X)
  • Substrate Solution D
  • Coating Buffer A (5X)
  • Assay Diluent A (5X)

Older lots of these products may contain Substrate Solutions A and B instead of Substrate Solution D mentioned on the TDS and the current manual. Please refer to the lot-specific CoA for the list of the reagents included in the lot and follow the ELISA procedure provided there.

Materials Not Included
  • Microwell plates: 96-well Nunc MaxiSorp™ is recommended.
  • A microplate reader capable of measuring absorbance at 450 nm
  • Adjustable pipettes to measure volumes ranging from 2 µL to 1 mL
  • Deionized (DI) water
  • PBS (Phosphate-Buffered Saline): 8.0 g NaCl, 1.16 g Na2HPO4, 0.2 g KH2PO4, 0.2 g KCl, add deionized water to 1 L; pH to 7.4, 0.2 µm filtered.
  • Wash Buffer (Phosphate-Buffered Saline (PBS) + 0.05% Tween-20, pH=7.4). BioLegend Cat. No. 421601 is recommended.
  • Wash bottle or automated microplate washer
  • Stop Solution (e.g. 2N H2SO4) Biolegend Cat. No. 423001 is recommended
  • Log-Log graph paper or software for data analysis
  • Tubes to prepare standard dilutions
  • Timer
  • Plate Sealer
  • Absorbent paper

Product Details

Verified Reactivity
Human
Application

ELISA
 
As a part of BioLegend's efforts to go green, each new lot of the ELISA MAX™ sets will include a summarized version of its manual. Click here for more information.
Application Notes

The assay kits will no longer include ELISA microwell plates. Recommended microwell plates can be purchased separately under Cat. No. 423501. Please contact your BioLegend sales representative for bulk pricing quotations.

Application References
  1. Ye Z, et al. 2008. Infect Immun. 75:2541. PubMed
  2. Zhang Y, et al. 2010. Infect Immun. 78:2329. PubMed
  3. Peng J, et al. 2005. J. Immunother. 28:599. PubMed
  4. Bendersky A, et al. 2012. J. Immunol. 188:4349. PubMed
  5. Boggio E, et al. 2012. Hum Immunol. 73:585. PubMed
  6. Ankrum JA, et al. 2014. Sci Rep. 4:4645. PubMed
  7. Wu Z, et al. 2015. J Virol. 89:2906. PubMed
Product Citations
  1. Klement JD, et al. 2018. J Clin Invest. 128:5549. PubMed
  2. Wu Z, et al. 2015. J Virol. 89:2906. PubMed
  3. Cordoba S, et al. 2021. Nat Med. 27:1797. PubMed
  4. Heitzeneder S, et al. 2022. Cancer Cell. 40:53. PubMed
  5. Shemesh A, et al. 2022. J Exp Med. 219: . PubMed
  6. Bigenwald C, et al. 2023. Oncoimmunology. 12:2163785. PubMed
  7. Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed
  8. Labanieh L, et al. 2022. Cell. 185:1745. PubMed
  9. McKenzie C, et al. 2023. Mol Ther Nucleic Acids. 32:603. PubMed
  10. Leland P, et al. 2023. J Transl Med. 21:367. PubMed
  11. Loh HP, et al. 2023. MAbs. 2231129:15. PubMed
  12. Scurr MJ, et al. 2022. Nat Commun. 13:5422. PubMed
  13. Bröker K, et al. 2019. J Transl Med. 17:6. PubMed
  14. Meryk A et al. 2019. Cell reports. 26(10):2681-2691 . PubMed
  15. Kilcollins A, et al. 2016. J Immunol. 197: 419 - 428. PubMed
  16. Pires D, et al. 2021. Front Immunol. 12:742822. PubMed
  17. Singhal J, et al. 2022. Front Cell Infect Microbiol. 12:878136. PubMed
  18. Wang H, et al. 2021. J Immunother Cancer. 9:. PubMed
  19. Singh N, et al. 2018. PLoS One. 13:e0199817. PubMed
  20. Boggio E, et al. 2012. Hum Immunol. 73:585. PubMed
  21. Booty MG, et al. 2022. J Immunol. 208:929. PubMed
  22. Bendersky A, et al. 2012. J Immunol. 188:4349. PubMed
  23. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  24. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  25. Ankrum J, et al. 2014. Sci Rep. 4:4645. PubMed
  26. You Y, et al. 2021. Mol Med Rep. 24:. PubMed
  27. Karampetsou M, et al. 2016. J Immunol. 196: 4915 - 4924. PubMed
  28. Aldeghaither DS, et al. 2019. Cancer Immunol Res. 7:230. PubMed
  29. Kofla G, et al. 2022. Oncoimmunology. 11:2068109. PubMed
  30. Godbersen C, et al. 2017. Mol Cancer Ther. 16:1335. PubMed
  31. Sp N, et al. 2021. Int J Mol Sci. 22:. PubMed
  32. Hirschberger S, et al. 2022. Front Med (Lausanne). 9:923502. PubMed
  33. Liu CA, et al. 2022. Cancers (Basel). 14:. PubMed
  34. Madison BB, et al. 2022. Mol Ther Nucleic Acids. 29:979. PubMed
  35. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  36. Fernandes RA, et al. 2020. Nature. 779:586. PubMed
  37. Bliska Y 2010. Infect Immun. 78:2359. PubMed
  38. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  39. Wu Z, et al. 2019. Microorganisms. 0.670833333. PubMed
  40. Trinklein ND, et al. 2019. MAbs. 11:639. PubMed
  41. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  42. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  43. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  44. Subramanian N, et al. 2017. J Gen Virol. 98(12). PubMed
  45. Zhang X, et al. 2019. Hematol Oncol. 37(3):270. PubMed
  46. Kang CH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  47. Iraqi M, et al. 2022. Int J Mol Sci. 23:. PubMed
  48. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  49. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  50. Dammermann W, et al. 2017. J Virol Methods. 10.1016/j.jviromet.2017.07.011. PubMed
  51. Wang E, et al. 2015. Cancer Immunol Res. 3: 815 - 826. PubMed
  52. Kunyanee C, et al. 2016. PLoS One. 11: 0160741. PubMed
  53. Lei W, et al. 2022. Blood Cancer J. 12:35. PubMed
  54. Lucchesi D, et al. 2020. Arthritis Rheumatol. 1559:72. PubMed
  55. Singh N, et al. 2017. Mol Immunol. 85:111. PubMed
  56. Klement JD, et al. 2018. J Clin Invest. 128:5549. PubMed
  57. Wu Z, et al. 2015. J Virol. 89:2906. PubMed
  58. Cordoba S, et al. 2021. Nat Med. 27:1797. PubMed
  59. Heitzeneder S, et al. 2022. Cancer Cell. 40:53. PubMed
  60. Shemesh A, et al. 2022. J Exp Med. 219: . PubMed
  61. Bigenwald C, et al. 2023. Oncoimmunology. 12:2163785. PubMed
  62. Sheng YR, et al. 2022. Cell Mol Life Sci. 79:173. PubMed
  63. Labanieh L, et al. 2022. Cell. 185:1745. PubMed
  64. McKenzie C, et al. 2023. Mol Ther Nucleic Acids. 32:603. PubMed
  65. Leland P, et al. 2023. J Transl Med. 21:367. PubMed
  66. Loh HP, et al. 2023. MAbs. 2231129:15. PubMed
  67. Scurr MJ, et al. 2022. Nat Commun. 13:5422. PubMed
  68. Bröker K, et al. 2019. J Transl Med. 17:6. PubMed
  69. Meryk A et al. 2019. Cell reports. 26(10):2681-2691 . PubMed
  70. Kilcollins A, et al. 2016. J Immunol. 197: 419 - 428. PubMed
  71. Pires D, et al. 2021. Front Immunol. 12:742822. PubMed
  72. Singhal J, et al. 2022. Front Cell Infect Microbiol. 12:878136. PubMed
  73. Wang H, et al. 2021. J Immunother Cancer. 9:. PubMed
  74. Singh N, et al. 2018. PLoS One. 13:e0199817. PubMed
  75. Boggio E, et al. 2012. Hum Immunol. 73:585. PubMed
  76. Booty MG, et al. 2022. J Immunol. 208:929. PubMed
  77. Bendersky A, et al. 2012. J Immunol. 188:4349. PubMed
  78. Ye Z, et al. 2008. Infect Immun. 76:2541. PubMed
  79. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  80. Ankrum J, et al. 2014. Sci Rep. 4:4645. PubMed
  81. You Y, et al. 2021. Mol Med Rep. 24:. PubMed
  82. Karampetsou M, et al. 2016. J Immunol. 196: 4915 - 4924. PubMed
  83. Aldeghaither DS, et al. 2019. Cancer Immunol Res. 7:230. PubMed
  84. Kofla G, et al. 2022. Oncoimmunology. 11:2068109. PubMed
  85. Godbersen C, et al. 2017. Mol Cancer Ther. 16:1335. PubMed
  86. Sp N, et al. 2021. Int J Mol Sci. 22:. PubMed
  87. Hirschberger S, et al. 2022. Front Med (Lausanne). 9:923502. PubMed
  88. Liu CA, et al. 2022. Cancers (Basel). 14:. PubMed
  89. Madison BB, et al. 2022. Mol Ther Nucleic Acids. 29:979. PubMed
  90. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  91. Fernandes RA, et al. 2020. Nature. 779:586. PubMed
  92. Bliska Y 2010. Infect Immun. 78:2359. PubMed
  93. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  94. Wu Z, et al. 2019. Microorganisms. 0.670833333. PubMed
  95. Trinklein ND, et al. 2019. MAbs. 11:639. PubMed
  96. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  97. Hirschberger S, et al. 2021. EMBO Mol Med. 13:e14323. PubMed
  98. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  99. Subramanian N, et al. 2017. J Gen Virol. 98(12). PubMed
  100. Zhang X, et al. 2019. Hematol Oncol. 37(3):270. PubMed
  101. Kang CH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  102. Iraqi M, et al. 2022. Int J Mol Sci. 23:. PubMed
  103. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  104. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  105. Dammermann W, et al. 2017. J Virol Methods. 10.1016/j.jviromet.2017.07.011. PubMed
  106. Wang E, et al. 2015. Cancer Immunol Res. 3: 815 - 826. PubMed
  107. Kunyanee C, et al. 2016. PLoS One. 11: 0160741. PubMed
  108. Lei W, et al. 2022. Blood Cancer J. 12:35. PubMed
  109. Lucchesi D, et al. 2020. Arthritis Rheumatol. 1559:72. PubMed
  110. Singh N, et al. 2017. Mol Immunol. 85:111. PubMed
Sensitivity
4 pg/mL
Standard Range
7.8-500 pg/mL

Antigen Details

Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Type
Tregs
Biology Area
Immunology, Innate Immunity, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Gene ID
3458 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

Do the ELISA MAX™ Deluxe Sets come with plates?

No, ELISA MAX™ Deluxe Sets do not come with plates. Coating Buffer and Assay Diluent (for blocking and dilutions) are included in these sets. Plates can be ordered separately (Cat No. 423501), and instructions for coating the plates are in the sets’ product manuals.

Go To Top Version: 6    Revision Date: 07.15.2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account